BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Debt Growth

The Year-over-Year Debt Growth of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is -11.30 %. In the previous year, Year-over-Year Debt Growth was -3.07 % — a change of 267.47% (lower).

Debt Growth

-11.30 %

YoY

267.47%

Last updated:

Year-over-Year Debt Growth of BrightGene Bio-Medical Technology Co is 2025 -11.30 % . Year-over-Year Debt Growth of BrightGene Bio-Medical Technology Co was 2024 -3.07 % . It decreases by 267.47% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2021
698.15 CNY
Jan 1, 2022
154.74 CNY
Jan 1, 2023
2.47 CNY
Jan 1, 2024
-3.07 CNY
Jan 1, 2025
-11.30 CNY
The BrightGene Bio-Medical Technology Co Debt Growth history
YEARDebt GrowthYoY
-11.30 %+267.47%
-3.07 %-224.65%
2.47 %-98.41%
154.74 %-77.84%
698.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Year-over-Year Debt Growth of BrightGene Bio-Medical Technology Co is -11.30 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co